Increased activity of the Src tyrosine protein kinase that has been observed in a large number of human malignancies appears to be a promising target for drug therapy. In the present study, a critical role of the Src activity in the deregulation of mTOR signaling pathway in Rous sarcoma virus (RSV)-transformed hamster fibroblasts, H19 cells, was shown using these cells treated with the Src-specific inhibitor, SU6656, and clones of fibroblasts expressing either the active Src or the dominant-negative Src kinase-dead mutant. Disruption of the Src kinase activity results in substantial reduction of the phosphorylation and activity of the Akt/protein kinase B (PKB), phosphorylation of tuberin (TSC2), mammalian target of rapamycin (mTOR), S6K1, ribosomal protein S6, and eukaryotic initiation factor 4E-binding protein 4E-BP1. The ectopic, active Akt1 that was expressed in Src-deficient cells significantly enhanced phosphorylation of TSC2 in these cells, but it failed to activate the inhibited components of the mTOR pathway that are downstream of TSC2. The data indicate that the Src kinase activity is essential for the activity of mTOR-dependent signaling pathway and suggest that mTOR targets may be controlled by Src independently of Akt1/TSC2 cascade in cells expressing hyperactive Src protein. These observations might have an implication in drug resistance to mTOR inhibitor-based cancer therapy in certain cell types.

Institute of Molecular Genetics Academy of Sciences of the Czech Republic Prague Czech Republic

See more in PubMed

Wullschleger S, Loewit R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124:471–484. PubMed

Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and RAPTOR-independent pathway that regulates the cytoskeleton. Curr Biol. 2004;14:1296–1302. PubMed

Fonseca BD, Smith EM, Lee VH, MacKintosh C, Proud CG. PRAS40 is a target for mammalian target of rapamycin complex 1 and is required for signaling downstream of this complex. J Biol Chem. 2007;282:24514–24524. PubMed

Sancak Y, Thoreen CC, Peterson TR, Lindquist RA, Kang SA, Spooner E, Carr SA, Sabatini DM. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell. 2007;25:903–915. PubMed

Holland EC, Sonenberg N, Pandolfi PP, Thomas G. Signaling control of mRNA translation in cancer pathogenesis. Oncogene. 2004;23:3138–3144. PubMed

Long X, Lin Y, Ortiz-Vega S, Yonezawa K, Avruch J. Rheb binds and regulates the mTOR kinase. Curr Biol. 2005;15:702–713. PubMed

Tee AR, Manning BD, Roux PP, Cantley LC, Blenis J. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol. 2003;13:1259–1268. PubMed

Smith EM, Fin SG, Tee AR, Browne GJ, Proud CG. The tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian target of rapamycin by amino acids and certain cellular stresses. J Biol Chem. 2005;280:18717–18727. PubMed

Cai SL, Tee AR, Short JD, Bergeron JM, Kim J, Shen J, Guo R, Johnson CL, Kiquchi K, Walker CL. Activity of TSC2 is inhibited by Akt-mediated phosphorylation and membrane partitioning. J Cell Biol. 2006;173:279-–289. PubMed PMC

Inoki K, Guan KL. Complexity of the TOR signaling network. Trends Cell Biol. 2006;16:206–212. PubMed

Roux PP, Ballif BA, Anjum R, Gygi SP, Blenis J. Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc Natl Acad Sci USA. 2004;101:13489–13494. PubMed PMC

Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell. 2007;129:1261–1274. PubMed PMC

Chen R, Kim O, Yang Y, Sato K, Eisenmann KM, McCarthy J, Chen H, Qiu Y. Regulation of PKB/Akt activation by tyrosine phosphorylation. J Biol Chem. 2001;276:31858–31862. PubMed

Jiang T, Qiu Y. Interaction between Src and C-terminal proline-rich motif of Akt is required for Akt activation. J Biol Chem. 2003;278:15789–15793. PubMed

Conus NM, Hannan KM, Cristiano BE, Hemmings BA, Pearson RB. Direct identification of tyrosine 474 as a regulatory phosphorylation site for the Akt protein kinase. J Biol Chem. 2002;277:38021–38028. PubMed

Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of PKB/Akt by the rictor-mTOR complex. Science. 2005;307:1098–1101. PubMed

Han EK, Leverson JD, McGonigal T, Shah OJ, Woods KW, Hunter T, Giranda VL, Luo Y. Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition. Oncogene. 2007;26:5655–5661. PubMed

O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006;66:1500–1508. PubMed PMC

Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H, Khuri FR. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res. 2005;65:7052–7058. PubMed

Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL, Sabatini DM. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell. 2006;22:159–168. PubMed

Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Cordon-Cardo C, Pelletier J, Lowe SW. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature. 2004;428:332–337. PubMed

Vojtěchová M, Šloncová E, Kučerová D, Jiřička J, Sovová V, Tuháčková Z. Initiation factor eIF2B not p70 S6 kinase is involved in the activation of the PI3-K signaling pathway induced by the v-src oncogene. FEBS Lett. 2003;543:81–86. PubMed

Vojtěchová M, Šenigl F, Šloncová E, Tuháčková Z. Regulation of Src activity by the expression of wild-type v-Src and its kinase-dead double Y416F-K295N mutant. Arch Biochem Biophys. 2006;455:136–143. PubMed

Krieg J, Olivier AR, Thomas G. In: Methods in Enzymology: Analysis of 40S Ribosomal Protein S6 Phosphorylation During Mitogenic Response. Noller HF Jr, Moldave K, editors. New York: Academic Press; 1988. pp. 571–581. PubMed

Kohn AD, Barthel A, Kovacina KS, Boge A, Wallach B, Summers SA, Birnbaum MJ, Scott PH, Lawrence JC, Roth RA. Construction and characterization of a conditionally active version of the serine/threonine kinase Akt. J Biol Chem. 1998;273:11937–11943. PubMed

Turečková J, Wilson EM, Cappalonga JL, Rotwein P. Insulin-like growth factor-mediated muscle differentiation. J Biol Chem. 2001;276:39264–39270. PubMed

Karni R, Gus Y, Dor Y, Meyuhas O, Levitzki A. Active Src elevates the expression of β-catenin by enhancement of cap-dependent translation. Mol Cell Biol. 2005;25:5031–5039. PubMed PMC

Shah OJ, Kimball SR, Jefferson LS. The Src-family kinase inhibitor PP1 interferes with the activation of ribosomal protein S6 kinases. Biochem J. 2002;366:57–62. PubMed PMC

Tuháčková Z, Sovová V, Šloncová E, Proud CG. Rapamycin-resistant phosphorylation of the initiation factor-4E-binding protein (4E-BP1) in v-Src-transformed hamster fibroblasts. Int J Cancer. 1999;81:963–969. PubMed

Blake RA, Broome MA, Liu X, Wu J, Gishizky M, Sun L, Courtneidge S. SU6656, a selective Src family kinase inhibitor, used to probe growth factor signaling. Mol Cell Biol. 2000;20:9018–9027. PubMed PMC

Holz MK, Blenis J. Identification of S6 kinase 1 as a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase. J Biol Chem. 2005;280:26089–26093. PubMed

Chiang GG, Abraham RT. Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase. J Biol Chem. 2005;280:25485–25490. PubMed

Rebholz H, Panasyuk G, Fenton T, Nemazanyy I, Valovka T, Flajolet M, Ronnstrand L, Stephens L, West A, Gout IT. Receptor association and tyrosine phosphorylation of S6 kinases. FEBS J. 2006;273:2023–2036. PubMed

Jin W, Yun C, Hobbie A, Martin MJ, Sorensen PHB, Kim SJ. Cellular transformation and activation of the phosphoinositide-3-kinase-Akt cascade by the ETV6-NTRK3 chimeric tyrosine kinase requires c-Src. Cancer Res. 2007;67:3192–3200. PubMed

Deutsch E, Maggiorella L, Wen B, Bonnet ML, Khanfir K, Frascogna V, Turhan AG, Bourhis J. Tyrosine kinase inhibitor AG1024 exerts antileukaemic effects on STI571-resistant Bcr-Abl expressing cells and decreases AKT phosphorylation. Br J Cancer. 2004;91:1735–1741. PubMed PMC

VanderWeele DJ, Zhou R, Rudin CM. Akt up-regulation increases resistance to microtubule-directed chemotherapeutic agents through mammalian target of rapamycin. Mol Cancer Ther. 2004;3:1605–1613. PubMed

Puttini M, Coluccia AML, Boschelli F, Cleris L, Marchesi E, Donella-Deana A, Ahmed S, Redaelli S, Piazza R, Magistroni V, et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl neoplastic cells. Cancer Res. 2006;66:11314–11322. PubMed

Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR. mTOR interacts with RAPTOR to form nutrient-sensitive complex that signals to the cell growth machinery. Cell. 2002;110:163–175. PubMed

Thomas GV, Tran C, Mellinghoff IK, Welsbie DS, Chan E, Fueger B, Czernin J, Sawyers CL. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med. 2006;12:122–127. PubMed

Brugge J, Hung MC, Mills GB. A new mutational aktivation in the PI3K pathway. Cancer Cell. 2007;12:104–107. PubMed